Search

Biomass production in marginal lands represents one of the most challenging and promising alternatives to sustainably produce biofuels. Native species seem to be the most adequate option to obtain a profitable output when low-input techniques are applied, and biomass is grown in depleted soils and harsh climatic conditions. In this study, a 5-year field trial in the island of Majorca served to investigate different autochthonous and naturalized Mediterranean perennial grasses as novel candidate lignocellulosic bioenergy crops for the semi-arid Mediterranean area and compare them with commercial ones (both Mediterranean and non-Mediterranean). Species and growing season had a significant effect on biomass production, perennialism and biomass quality. Arundo donax (winter crops) and Piptatherum miliaceum (autumn crops) performed better than the commercial species tested (Panicum virgatum for winter crops and Festuca arundinacea for autumn crops) in biomass production and perennialism. In terms of biomass quality, Panicum virgatum was the best species, having high structural content (mainly cellulose and hemicellulose), low non-structural content and the lowest ash. However, Ampelodesmos mauritanicus and Arundo donax rendered similar results, with no significant difference in terms of cellulose production for this latter but with higher lignin content. For the autumn species, Festuca arundinacea was the species with the best biomass quality but with the highest ash production for all the species considered. Hence, both for winter or autumn regimes, native or naturalized plants seem to be better suited than the commercial commonly used for biomass production with energy-producing purposes. Further research must be conducted in terms of seed biology and physiology, seedbed preparation methods, sowing time, seedling density and weed control before they can firmly be proposed as adequate alternatives for energy purposes. [ABSTRACT FROM AUTHOR]

The majority of recombinant mAb products contain heterogeneous charge variants, commonly the result of post-translational modifications occurring during cell culture and accumulated during production, formulation and storage. MB02 is a biosimilar mAb to bevacizumab. Similarity data of charge variants for biosimilars against its reference products must be generated to demonstrate consistency in product quality and to ensure efficacy and safety. The goal of this work was to isolate seven charge variants of MB02 and Avastin® by semi-preparative cation exchange chromatography followed by purity test and extended analytical characterization to prove similarity. Although poor purity obtained for minor variants complicated data interpretation, an in-depth insight into the charge variants pattern of MB02 compared to Avastin® was obtained, contributing to a better understanding of modifications associated to microheterogeneity. To our knowledge, this is the first comparative analytical study of individual charge variants of a bevacizumab biosimilar following a head-to head approach and the most comprehensive N-glycosylation assessment of IgG1 charge variants. Although modifications related to N- and C-terminal, N-glycans, size heterogeneity or deamidation were specifically enriched among low abundant charge variants, they did not affect binding affinity to VEGF or FcRn and in vitro potency compared with the main species or unfractionated material. [ABSTRACT FROM AUTHOR]

The majority of recombinant mAb products contain heterogeneous charge variants, commonly the result of post-translational modifications occurring during cell culture and accumulated during production, formulation and storage. MB02 is a biosimilar mAb to bevacizumab. Similarity data of charge variants for biosimilars against its reference products must be generated to demonstrate consistency in product quality and to ensure efficacy and safety. The goal of this work was to isolate seven charge variants of MB02 and Avastin® by semi-preparative cation exchange chromatography followed by purity test and extended analytical characterization to prove similarity. Although poor purity obtained for minor variants complicated data interpretation, an in-depth insight into the charge variants pattern of MB02 compared to Avastin® was obtained, contributing to a better understanding of modifications associated to microheterogeneity. To our knowledge, this is the first comparative analytical study of individual charge variants of a bevacizumab biosimilar following a head-to head approach and the most comprehensive N-glycosylation assessment of IgG1 charge variants. Although modifications related to N- and C-terminal, N-glycans, size heterogeneity or deamidation were specifically enriched among low abundant charge variants, they did not affect binding affinity to VEGF or FcRn and in vitro potency compared with the main species or unfractionated material. [ABSTRACT FROM AUTHOR]